{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:06:32Z","timestamp":1774404392133,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijantimicag.2022.106699","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T21:35:22Z","timestamp":1669930522000},"page":"106699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A descriptive pharmacokinetic\/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and\/or ventilator-associated pneumonia"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Pascale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Giorgio","family":"Cojutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ambretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-9674","authenticated-orcid":false,"given":"Matteo","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":false,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106699_bib0001","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/jama.2016.11764","article-title":"Antimicrobial Resistance","volume":"316","author":"Marston","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0003","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: A systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0004","doi-asserted-by":"crossref","DOI":"10.1097\/QCO.0000000000000755","article-title":"Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections","author":"Gatti","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/phar.2210","article-title":"Pharmacokinetics and pharmacodynamics of \u03b2-lactamase inhibitors","volume":"39","author":"Crass","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0006","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0007","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/antibiotics10111311","article-title":"Assessment of a PK\/PD Target of continuous infusion beta-lactams useful for preventing microbiological failure and\/or resistance development in critically ill patients affected by documented gram-negative infections","volume":"10","author":"Gatti","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0009","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm.165.7.2105078","article-title":"Ventilator-associated pneumonia","volume":"165","author":"Chastre","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0010","unstructured":"Ceftazidime-avibactam summary of product characteristics n.d."},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0011","unstructured":"EUCAST - Rationale for EUCAST clinical breakpoints - Ceftazidime-avibactam 2020."},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0012","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4155\/bio.15.76","article-title":"Determination of avibactam and ceftazidime in human plasma samples by LC-MS","volume":"7","author":"Sill\u00e9n","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40261-015-0283-9","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies","volume":"35","author":"Merdjan","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13054-022-04050-9","article-title":"Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients","volume":"26","author":"Gatti","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0017","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2021.04.015","article-title":"Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime-avibactam: a retrospective cohort study","author":"Goncette","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0020","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/17512433.2021.1901574","article-title":"Pharmacokinetic\/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams\/beta-lactamase inhibitors","author":"Gatti","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0022","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal dosing of antibiotics: are we jumping the gun?","volume":"68","author":"Crass","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106699_bib0023","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:11Z","timestamp":1760377451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922002254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0924857922002254"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106699","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A descriptive pharmacokinetic\/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and\/or ventilator-associated pneumonia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106699"}}